2023 · NPJ precision oncology · open access
Adashek & Kurzrock
Decentralised and site-less trial designs enable broader participation in rare cancer studies by mitigating travel burdens for underserved and rural populations.
A paraphrase to the Library’s standard, never the abstract. The source is one link away and is always the authority.
2026
Ten decentralised cancer trials run across 47 Veterans Affairs medical centres enrolled 134 patients, nearly a third of them rural and a fifth from minority groups, matching the population the VA's tele-oncology service already reaches. The authors' own caveat stands: remote conduct widened access, and not every trial design can be run this way.
Friedman et al., Journal of the National Cancer Institute (paywalled) · source ↗
2026
This review suggests that decentralised clinical trials in oncology can improve patient participation and equity but face significant regulatory, logistical and digital hurdles. It concludes that these trials offer a flexible model dependent on specific clinical contexts rather than a universal replacement for conventional methods.
Gentile et al., Critical reviews in oncology/hematology (paywalled) · source ↗
2026
Hybrid decentralized oncology trials are feasible in community hospitals beyond traditional networks, reducing logistical and financial burdens and enabling rapid initiation and patient referrals within three months.
Morrison et al., The oncologist · source ↗
2026
A nationwide survey of 194 professionals across 140 Japanese hospitals found that geographic and logistical barriers limit access to comprehensive genomic profiling and genotype-matched trials, with over half of eligible patients declining participation due to travel distance; most institutions support telemedicine for consent and results and view DCTs as essential to improve equitable access.
Taniguchi et al., International journal of clinical oncology · source ↗
2025
Decentralised clinical trials can help overcome barriers to trial participation such as travel burdens and improve access to recommended treatments.
Sasaki & Nakamura, Gan to kagaku ryoho. Cancer & chemotherapy (paywalled) · source ↗